Showing results (301-310 of 389) with videos related to
Sort By:
Pageof 39
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 4, 2009
Phase II trial of amrubicin for second-line treatment of advanced non-small cell lung cancer: results of the West Japan Thoracic Oncology Group trial (WJTOG0401)Hiroyasu Kaneda, Isamu Okamoto, Hidetoshi Hayashi, et al.The American Journal of Pathology|February 13, 2002
Proteolytic cleavage of the CD44 adhesion molecule in multiple human tumorsIsamu Okamoto, Hiromasa Tsuiki, Lawrence C Kenyon, et al.Cancer Treatment and Research Communications|October 2, 2025
Study protocol of an open-label prospective phase II study of Durvalumab plus Carboplatin and Etoposide in advanced large cell neuroendocrine carcinoma of the lung (LOGIK2401: NECTAR study)Hidenobu Ishii, Koichi Azuma, Fumiaki Kiyomi, et al.Clinical Lung Cancer|May 22, 2026
Predicting Radiation-Induced Esophagitis in Locally Advanced NSCLC Using Baseline Clinical Factors: A Model From the Japan Lung Cancer Society Integrated Phase II-III DatabaseYuji Uehara, Kageaki Watanabe, Jun Tamura, et al.The Oncologist|October 26, 2019
Updated Survival Data for a Phase I/II Study of Carboplatin plus Nab-Paclitaxel and Concurrent Radiotherapy in Patients with Locally Advanced Non-Small Cell Lung CancerYuko Tsuchiya-Kawano, Tomonari Sasaki, Hiroyuki Yamaguchi, et al.International Journal of Clinical Oncology|August 7, 2023
First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1Makoto Nishio, Yuichiro Ohe, Satoshi Ikeda, et al.The Journal of Clinical Investigation|June 10, 2014
CRIPTO1 expression in EGFR-mutant NSCLC elicits intrinsic EGFR-inhibitor resistanceKang-Seo Park, Mark Raffeld, Yong Wha Moon, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 2, 2021
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT)Hirohito Tada, Tetsuya Mitsudomi, Toshihiro Misumi, et al.JAMA Oncology|March 13, 2020
Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-Small Cell Lung Cancer: A Phase 3 Randomized Clinical TrialIsamu Okamoto, Hiroshi Nokihara, Shogo Nomura, et al.Lung Cancer (Amsterdam, Netherlands)|September 20, 2025
Biological impact of chemotherapy during treatment with EGFR tyrosine kinase inhibitors for non-small cell lung cancer positive for EGFR activating mutationsEiji Iwama, Kazuko Sakai, Taishi Harada, et al.Pageof 39